OBM Transplantation

(ISSN 2577-5820)

OBM Transplantation is an international peer-reviewed Open Access journal, which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.

OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.

We welcome original clinical studies as well as basic science, reviews, short reports/rapid communications, case reports, opinions, technical notes, book reviews as well as letters to the editor. 

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 7 days from acceptance to publication (median values for papers published in this journal in 2020, 1-2 days of FREE language polishing time is also included in this period). 

Current Issue: 2021  Archive: 2020 2019 2018 2017

Special Issue

Allogeneic Stem Cell Transplantation

Submission Deadline: January 30, 2021 (Open) Submit Now

Guest Editor

Martin Guimond, PhD

Associate Professor, Department of Microbiology, Infection, and Immunology, University of Montreal, Montreal, Quebec, Canada; Research Center, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada

Website | E-Mail

Research Interests: T Lymphocytes; immunomodulation; allogeneic stem cell transplatation; stem cell transplantation; graft-versus-host disease; immunology

About this topic

In 1980, the New England Journal of Medicine published the first successful unrelated bone marrow transplantation to treat acute leukemia. Since then, the field of stem cell transplantation has evolved considerably. Today, allogeneic-SCT remains the only curative treatment for several patients with high risk refractory hematologic cancers. Recently, clinical trials were developed to evaluate the use of Allogeneic Stem Cell transplantation to treat/cure solid tumors. This Special Issue will cover new developments in the field of Allogeneic Stem Cell Transplantation including new procedures in Allogeneic Stem cell Transplantation, conditioning regiments, stem cell source, strategies to reduce/control acute or chronic graft-versus-host disease (T cell depletion, mesenchymal stem cells, suicide genes…), modulation of graft-versus leukemia (cytokines, CAR-T cells), management of infectious complications, strategies to improve immune reconstitution, in vitro and in vivo studies, animal models, and clinical trials on Allogeneic Stem Cell Transplantation. Original research papers, mini and full reviews and commentaries are all welcome. There is no restriction on the length of the manuscripts. Peer-review is commissioned immediately upon receipt of the manuscript.


Open Access Research Article

Umbilical Cord Blood as an Alternate Donor Sources for High Risk Elderly Patients Undergoing Allogeneic Stem Cell Transplantation for Hematological Malignancies

Received: 04 November 2020;  Published: 07 February 2021;  doi: 10.21926/obm.transplant.2101136


Allogeneic stem cell transplantation remains the only curative option for many hematological malignancies. Umbilical cord blood (UCB) is an alternate donor source with potentially increased morbidity in elderly patients. We evaluated outcomes in alternate donor sources, prior to the initiation of ha [...]
Open Access Original Research

“Real World” Australian Experience of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adults with Severe Aplastic Anaemia.

Received: 23 June 2020;  Published: 23 October 2020;  doi: 10.21926/obm.transplant.2004121


Acquired Severe Aplastic Anaemia (SAA) is a rare bone marrow failure syndrome, for which allogeneic haematopoietic stem cell transplant (HSCT) is a proven curative therapy. Despite excellent outcomes for matched sibling SAA recipients in terms of engraftment and survival, HSCT remains highly challen [...]